

**What Is Claimed Is:**

1       1. A peptide of eight to twenty amino acids in  
2 length which comprises a hydrophilic analog of an alpha-  
3 fetoprotein peptide having SEQ ID NO:6: EMTPVNPG.

1       2. The peptide of claim 1 wherein the peptide is  
2 linear.

1       3. The peptide of claim 1 wherein the peptide is  
2 cyclic.

1       4. The peptide of claim 1 wherein one or more of  
2 the amino acids is a (D)-amino acid.

1       5. The peptide of claim 1 which comprises an amino  
2 acid sequence selected from the group consisting of:  
3           SEQ ID NO:2: QMTPVNPG,  
4           SEQ ID NO:3: QMTPVNRGE  
5           SEQ ID NO:4: EMTOVNOG  
6           SEQ ID NO:5: EMTOVNOGQ  
7           SEQ ID NO:7: EMTPVNPGQ  
8           SEQ ID NO:8: EMTOVNPG  
9           SEQ ID NO:9: EMTOVNPGQ  
10          SEQ ID NO:10: EMTPVNPG and  
11          SEQ ID NO:11: EMTPVNPGQ,  
12 or a peptidomimetic of said peptide.

1       6. The peptide of claim 1 labeled with a  
2 detectable marker.

1       7. The peptide of claim 6 wherein the detectable  
2 marker is a radiolabel.

1        8. The peptide of claim 7 wherein the radiolabel  
2 is a radiolabeled additional amino acid.

1        9. A dimeric peptide consisting of two peptides of  
2 claim 1.

*Mb AL*  
1        10. The dimeric peptide of claim 9 wherein the two  
2 peptides are SEQ ID NO:4 and SEQ ID NO:5.

1        11. The dimeric peptide of claim 9, wherein the two  
2 peptides are SEQ ID NO:3 and SEQ ID NO:10.

1        12. A multimeric peptide consisting of three or  
2 more peptides of claim 1.

1        13. A composition comprising the peptide of claim 1  
2 and a suitable carrier.

1        14. The composition of claim 13 wherein the  
2 suitable carrier includes a stabilization excipient.

1        15. The composition of claim 14 wherein the  
2 stabilization excipient is dodecyl maltoside or mannitol.

1        16. An antibody that specifically binds to the  
2 peptide of claim 1.

1        17. A method of reducing estrogen-stimulated growth  
2 of cells, the method comprising exposing cells to the  
3 peptide of claim 1.

1        18. The method of claim 17 which further comprises  
2 exposing the cells to tamoxifen before, during, or after  
3 exposing the cells to the peptide.

1        19. A method of treating or preventing cancer in a  
2 subject which comprises administering to the subject an  
3 amount of the peptide of claim 1' effective to treat or  
4 prevent cancer in the subject.

1        20. The method of claim 19 wherein the cancer is  
2 estrogen-dependent cancer. —

1        21. The method of claim 20 wherein the estrogen-  
2 dependent cancer is breast cancer.

1        22. The method of claim 19 which further comprises  
2 administering a suitable amount of tamoxifen to the  
3 subject before, during, or after administering the  
4 peptide to the subject.

432010 432022 432030